The emergence of drug-resistant bacterial strains and their associated challenges continue to be responsible for a sustained economic burden to the whole world, exemplified by the fact that the World Health Organization (WHO) declared antimicrobial resistance (AMR) as one of the top ten primary health concerns affecting humanity. Bacterial infections comprise the majority of microbial infections due to their prevalence in diseases, public health impact, variability of virulence, development of resistance and ease of transmission, therefore, antibacterial agents are the most common method to prevent and treat these infections. The spectrum of antibacterial activity encompasses a wide range of bacteria, however, certain bacterial strains such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter sp., Escherichia coli -collectively called ESKAPEE -have garnered public interest as they are known to 'escape' commonly used antibiotic treatment owing to multidrug resistance (MDR). Data from the Centers for Disease Control and Prevention (CDC) for the year 2020 suggests that six out of the eighteen listed antimicrobial-resistant bacterial threats namely Vancomycin-resistant Enterococcus (VRE), Carbapenem-resistant Acinetobacter baumannii (CRAB), Methicillin Resistant Staphylococcus Aureus (MRSA), Carbapenem-resistant Enterobacterales (CRE), Multidrug-Resistant Pseudomonas aeruginosa (MDR-PA) and Extended-spectrum beta-lactamase (ESBL) producing Enterobacterales incur a collective cost of more than $4.6 billion annually. MRSA strains remain a leading cause of infections worldwide, ranging from skin and soft tissue infections to more serious conditions such as bacteremia and endocarditis. Due to the rise in resistant species, some bacterial infections have become public health threads. For instance, tuberculosis, a serious lung disease requiring prolonged antibiotic therapy, is caused by Mycobacterium tuberculosis (MT). Many species of MT are resistant to the first-line oral antituberculosis agents isoniazid and rifampicin and are designated MDR TB. MDR TB requires the use of second-line drugs which require parenteral delivery and often have significant side effects, reducing the likelihood that treatment is completed and thus facilitating resistance. More extensively resistant variants such as extensively drug-resistant TB (XDR-TB) are resistant to second-line antitubercular therapies, and in rare cases, MT can be resistant to all available therapies (totally drug-resistant TB (TDR-TB). . Similarly, community-acquired pneumonia (CAP), which results most commonly due to infection of Streptococcus pneumoniae and Haemophilus influenzae, is the major cause of pneumonia related deaths, especially in newborn population. Constantly evolving antibioticresistant bacterial species emphasize the need for a systematic literature review and analysis in the antibacterial field.